{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:47:04Z","timestamp":1792021624711,"version":"4.4.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaci.2026.01.002","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T07:38:25Z","timestamp":1768894705000},"page":"575-587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biologics in the treatment of severe asthma in children and adults\u2014updates 2024-2025"],"prefix":"10.1016","volume":"157","author":[{"given":"Courtney L.","family":"Gaberino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Moraczewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0432-2704","authenticated-orcid":false,"given":"Leonard B.","family":"Bacharier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.01.002_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaci.2020.10.003","article-title":"2020 Focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group","volume":"146","author":"Cloutier","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib4","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/pai.14092","article-title":"Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study)","volume":"35","author":"Wedner","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib8","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","article-title":"Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials","volume":"13","author":"Bhatt","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib10","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa2312282","article-title":"Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age","volume":"390","author":"Chehade","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib12","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib13","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib14","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib15","author":"Jackson"},{"key":"10.1016\/j.jaci.2026.01.002_bib16","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1164\/rccm.201810-1868CI","article-title":"Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology","volume":"199","author":"Beasley","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1183\/09031936.04.00076604","article-title":"Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis","volume":"23","author":"Masoli","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.01.002_bib18","first-page":"16","article-title":"Clinical dose-response relationship of fluticasone propionate in adults with asthma","volume":"59","author":"Masoli","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2026.01.002_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"Jackson","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2026.01.002_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","article-title":"Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study","volume":"11","author":"Price","year":"2018","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2026.01.002_bib21","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","article-title":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis","volume":"133","author":"Haldar","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13223-019-0348-z","article-title":"Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial","volume":"15","author":"Ortega","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib23","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)","volume":"59","author":"Moore","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.01.002_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00404-2024","article-title":"Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study)","volume":"64","author":"Soendergaard","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.01.002_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","article-title":"Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial","volume":"13","author":"Ramakrishnan","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib26","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-term therapy response to anti-IL-5 biologics in severe asthma-a real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-world effectiveness and the characteristics of a \"super-responder\" to mepolizumab in severe eosinophilic asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2026.01.002_bib28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2026.01.002_bib29","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.jaip.2023.05.025","article-title":"Long-term real-world outcomes of mepolizumab and benralizumab among biologic-naive patients with severe eosinophilic asthma: experience of 3 years' therapy","volume":"11","author":"Fyles","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107348","article-title":"Severe asthma clinical remission after biologic treatment with anti-IL4\/IL13: a real-life experience","volume":"217","author":"Portacci","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the International Severe Asthma Registry and the US CHRONICLE Study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2026.01.002_bib32","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.jaip.2024.03.049","article-title":"Long-term effectiveness of anti-IL-4R therapy following suboptimal response to anti-IL-5\/5R therapy in severe eosinophilic asthma","volume":"12","author":"Gates","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib33","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaci.2024.05.023","article-title":"Anti-IL-4R versus anti-IL-5\/5R after anti-IL-5\/5R failure in asthma: an emulated target trial","volume":"154","author":"Valery","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib34","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01521-2023","article-title":"Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme","volume":"64","author":"Jackson","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.01.002_bib35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jaip.2023.10.012","article-title":"Tobacco exposure and efficacy of biologic therapy in patients with severe asthma: a nationwide study from the Danish Severe Asthma Register","volume":"12","author":"Baastrup Soendergaard","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib36","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1164\/rccm.202305-0808OC","article-title":"Association between T2-related comorbidities and effectiveness of biologics in severe asthma","volume":"209","author":"Wechsler","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib37","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S2213-2600(25)00287-5","article-title":"Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial","volume":"13","author":"De Corso","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib38","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jaci.2024.07.029","article-title":"Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: real-world US ADVANTAGE study","volume":"154","author":"Bleecker","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2024.100934","article-title":"Comparative efficacy of biologics for patients with inadequately controlled asthma: a network meta-analysis","volume":"17","author":"Kim","year":"2024","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2026.01.002_bib40","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jaip.2025.04.015","article-title":"Comparative effectiveness of dupilumab versus mepolizumab and benralizumab in asthma: a multinational retrospective cohort study","volume":"13","author":"Hung","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib41","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jaip.2025.05.023","article-title":"Assessing comparative effectiveness of biologics for severe asthma: the devil is in the details","volume":"13","author":"Busse","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib42","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1513\/AnnalsATS.202306-566OC","article-title":"Comparative effectiveness of mepolizumab, benralizumab, and dupilumab among patients with difficult-to-control asthma: a multicenter retrospective propensity-matched analysis","volume":"21","author":"Kearney","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jaci.2026.01.002_bib43","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jaip.2024.02.029","article-title":"Comparative impact of asthma biologics: a nationwide US claim-based analysis","volume":"12","author":"Al-Shaikhly","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib44","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jaip.2024.02.034","article-title":"Smaller differences in the comparative effectiveness of biologics in reducing asthma-related hospitalizations compared with overall exacerbations","volume":"12","author":"Akenroye","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"suppl 3","key":"10.1016\/j.jaci.2026.01.002_bib45","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2025.05.035","article-title":"Asthma remission in the context of other immune-mediated diseases","volume":"156","author":"Smolen","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl 3","key":"10.1016\/j.jaci.2026.01.002_bib46","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.jaci.2025.04.037","article-title":"A critical look at the lexicon, parameters, and limitations of asthma remission definitions","volume":"156","author":"Jackson","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl 3","key":"10.1016\/j.jaci.2026.01.002_bib47","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jaci.2025.05.033","article-title":"Consensus summary on the definition of asthma remission","volume":"156","author":"Katial","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis","volume":"13","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib49","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.jaip.2024.08.033","article-title":"Long-Term Clinical and sustained remission in severe eosinophilic asthma treated with mepolizumab: the REMI-M study","volume":"12","author":"Crimi","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib50","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00316-2024","article-title":"Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies","volume":"64","author":"Wechsler","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.01.002_bib51","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.anai.2024.04.031","article-title":"Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study","volume":"133","author":"Brightling","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib52","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2024.10.009","article-title":"Dupilumab induces long-term on-treatment clinical remission in patients with type 2 asthma","volume":"13","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2025.101107","article-title":"Discontinuation of biologic therapy in severe asthma: evidence and strategies for safe withdrawal: a scoping review","volume":"18","author":"Ramirez-Villamizar","year":"2025","journal-title":"World Allergy Organ J"},{"issue":"suppl 3","key":"10.1016\/j.jaci.2026.01.002_bib54","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaci.2025.05.034","article-title":"Current data on biologics: evaluating clinical remission in asthma","volume":"156","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib55","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2023.09.044","article-title":"Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma","volume":"154","author":"Bacharier","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib56","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jaip.2024.03.031","article-title":"Dupilumab reduces exacerbations independent of changes in biomarkers in moderate-to-severe asthma","volume":"12","author":"Pavord","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib57","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1164\/rccm.202310-1751LE","article-title":"Biomarkers associated with lung function decline and dupilumab response in patients with asthma","volume":"209","author":"Pavord","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1361891","article-title":"Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma","volume":"15","author":"Porsbjerg","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib59","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.jaip.2025.03.011","article-title":"Concurrent blood eosinophils and FeNO as biological therapy indicators in severe asthma: findings from the precision medicine intervention in severe asthma study","volume":"13","author":"Pham","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib60","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00782-2024","article-title":"Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma","volume":"65","author":"Hamada","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.01.002_bib61","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01497-2024","article-title":"Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma","volume":"65","author":"Soendergaard","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.01.002_bib62","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jaip.2024.04.026","article-title":"Multivariate cluster analyses to characterize asthma heterogeneity and benralizumab responsiveness","volume":"12","author":"Li","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib63","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-2600(24)00362-X","article-title":"Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial","volume":"13","author":"Castro","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib64","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2025.06.037","article-title":"Effect of dupilumab on small airways measured by airway oscillometry in VESTIGE","volume":"156","author":"Washko","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib65","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaci.2024.10.024","article-title":"Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype","volume":"155","author":"Domvri","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib66","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00512-2024","article-title":"Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Gauvreau","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.01.002_bib67","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jaci.2022.10.028","article-title":"Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma","volume":"151","author":"Chan","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib68","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jaci.2024.11.024","article-title":"Effects of dupilumab on mannitol airway hyperresponsiveness in uncontrolled severe asthma","volume":"155","author":"Stewart","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib69","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.anai.2025.07.024","article-title":"Type 2 biomarkers and airway hyper-responsiveness disconnect in patients with uncontrolled severe asthma taking benralizumab or dupilumab","volume":"135","author":"Greig","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(23)00303-X","article-title":"Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study","volume":"12","author":"Bacharier","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib71","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaip.2023.12.043","article-title":"Long-term safety of dupilumab in patients with moderate-to-severe asthma: TRAVERSE Continuation Study","volume":"12","author":"Maspero","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib72","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00139-2025","article-title":"Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study","volume":"66","author":"Ma","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.01.002_bib73","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jamadermatol.2025.1578","article-title":"Psoriasis risk in patients with atopic dermatitis treated with dupilumab","volume":"161","author":"Lin","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"suppl 2","key":"10.1016\/j.jaci.2026.01.002_bib74","doi-asserted-by":"crossref","first-page":"ii58","DOI":"10.1093\/bjd\/ljad498.060","article-title":"Conjunctivitis adverse events in dupilumab clinical trials","volume":"190","author":"Zirwas","year":"2024","journal-title":"BJD"},{"key":"10.1016\/j.jaci.2026.01.002_bib75","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1164\/rccm.202501-0246OC","article-title":"Prevention of cardiovascular and other systemic adverse outcomes in patients with asthma treated with biologics","volume":"211","author":"Sadatsafavi","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib76","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jaip.2025.01.037","article-title":"Anti-IL-5 treatment reduces infection-related adverse events: a meta-analysis of phase 3 clinical trials","volume":"13","author":"Lustberg","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib77","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2417184","article-title":"Long-term safety of mepolizumab for up to \u223c10 years in patients with severe asthma: open-label extension study","volume":"56","author":"Pavord","year":"2024","journal-title":"Ann Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib78","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jaip.2024.09.029","article-title":"Rheumatic adverse effects with biologics targeting type 2 inflammation in severe asthma: a VigiBase study","volume":"13","author":"Laux","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib79","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.jaip.2025.04.011","article-title":"Newly diagnosed eosinophilic granulomatosis with polyangiitis in patients on biologics for severe asthma: a multicenter case series","volume":"13","author":"Rupani","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib80","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/jdv.19794","article-title":"Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: a nationwide retrospective cohort study","volume":"38","author":"Avallone","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2026.01.002_bib81","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S2213-2600(24)00174-7","article-title":"An international consensus on the use of asthma biologics in pregnancy","volume":"13","author":"Naftel","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib82","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.anai.2024.05.014","article-title":"A systematic review and expert Delphi consensus recommendation on the use of vaccines in patients receiving dupilumab: a position paper of the American College of Allergy, Asthma and Immunology","volume":"133","author":"Lieberman","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib83","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaci.2024.08.001","article-title":"Race and ethnicity, not just insurance, is associated with biologics initiation in asthma and related conditions","volume":"155","author":"Akenroye","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib84","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaip.2025.03.006","article-title":"Real-world effectiveness of biologic therapy in allergic bronchopulmonary aspergillosis","volume":"13","author":"Carter","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib85","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.jaip.2024.03.029","article-title":"Suboptimal response to biologics in severe asthma-a marker of humoral immunodeficiencies","volume":"12","author":"Tiotiu","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.01.002_bib86","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.anai.2024.09.016","article-title":"Novel asthma treatments: advancing beyond approved novel step-up therapies for asthma","volume":"134","author":"Seluk","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib87","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01461-2024","article-title":"A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule","volume":"65","author":"Deiteren","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.01.002_bib88","article-title":"FRONTIER-3: a randomised phase 2a study to investigate tozorakimab (an anti-IL-33 mAb) in early onset asthma","author":"Corren","year":"2025","journal-title":"ERJ Open Research"},{"key":"10.1016\/j.jaci.2026.01.002_bib89","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib90","article-title":"A Multiple Ascending-dose Study With Verekitug, A Novel Antibody to the Human Thymic Stromal Lymphopoietin Receptor, in Adults With Asthma","volume":"209","author":"Singh","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib91","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jaci.2021.01.037","article-title":"PrecISE: precision medicine in severe asthma: an adaptive platform trial with biomarker ascertainment","volume":"147","author":"Israel","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl 68","key":"10.1016\/j.jaci.2026.01.002_bib92","article-title":"APATURA: a phase 2a study of elarekibep, an inhaled IL-4 receptor alpha inhibitor, in moderate-to-severe asthma","volume":"64","author":"Hugo","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2026.01.002_bib93","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/bcp.70262","article-title":"AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma","volume":"92","author":"Lundahl","year":"2026","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2026.01.002_bib94","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12931-025-03309-3","article-title":"ARTEMISIA: a mechanistic study of a novel Janus kinase 1 inhibitor to advance molecular understanding and precision medicine in asthma","volume":"26","author":"Dosanjh","year":"2025","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2026.01.002_bib95","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaci.2021.02.042","article-title":"Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: a randomized, controlled, proof-of-activity trial","volume":"148","author":"Braithwaite","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl 1","key":"10.1016\/j.jaci.2026.01.002_bib96","article-title":"Inhaled frevecitinib reduces sputum eosinophils and improves FEV1 and ACQ-6 in subjects with moderate to severe asthma treated with ICS\/LABA","volume":"211","author":"Singh","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib97","article-title":"Efficacy and safety of rilzabrutinib - a novel oral treatment in asthma: results from a double blind placebo controlled phase 2 study","volume":"209","author":"Laidlaw","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib98","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/JAA.S337284","article-title":"Efficacy and safety of masitinib in corticosteroid-dependent severe asthma: a randomized placebo-controlled trial","volume":"15","author":"Davidescu","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jaci.2026.01.002_bib99","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaci.2025.05.031","article-title":"Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma","volume":"156","author":"McDowell","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib100","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jaci.2024.07.020","article-title":"Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma","volume":"154","author":"Howell","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib101","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1164\/rccm.202310-1730OC","article-title":"Biomarker predictors of clinical efficacy of the anti-ige biologic omalizumab in severe asthma in adults: results of the SoMOSA study","volume":"210","author":"Djukanovi\u0107","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.01.002_bib102","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jaci.2025.06.025","article-title":"Identification of potential transcriptomic and microRNA markers to assess benralizumab effectiveness","volume":"156","author":"Hirai","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib103","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamapediatrics.2025.2044","article-title":"Inflammatory pathways in residual asthma exacerbations among mepolizumab-treated urban children: a secondary analysis of a randomized clinical trial","volume":"179","author":"Altman","year":"2025","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jaci.2026.01.002_bib104","doi-asserted-by":"crossref","first-page":"8191","DOI":"10.1038\/s41467-025-63629-2","article-title":"Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthma","volume":"16","author":"Gaberino","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2026.01.002_bib105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2024.01.031","article-title":"Activated sputum eosinophils associated with exacerbations in children on mepolizumab","volume":"154","author":"Wilson","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib106","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jama.2025.11227","article-title":"Discovering residual pathways driving asthma exacerbations in the era of biologic therapy","volume":"334","author":"Powell","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2026.01.002_bib107","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2025.06.034","article-title":"Single-cell transcriptomic profiling of eosinophils and airway immune cells in childhood asthma","volume":"156","author":"Doni Jayavelu","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.002_bib108","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaci.2023.01.002","article-title":"Biologics in the treatment of asthma in children and adolescents","volume":"151","author":"Bacharier","year":"2023","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926000096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926000096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:18:58Z","timestamp":1781511538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926000096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0091674926000096"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.01.002","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in the treatment of severe asthma in children and adults\u2014updates 2024-2025","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}